Comparative Pharmacology
Head-to-head clinical analysis: MAGNACORT versus NASONEX 24HR ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNACORT versus NASONEX 24HR ALLERGY.
MAGNACORT vs NASONEX 24HR ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Glucocorticoid receptor agonist; inhibits inflammatory mediators including cytokines, chemokines, and adhesion molecules; reduces nasal inflammation.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
2 sprays (50 mcg/spray) per nostril once daily; total dose 200 mcg/day.
None Documented
None Documented
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
The terminal elimination half-life of mometasone furoate is approximately 5.8 hours. This short half-life supports once-daily dosing for intranasal use, but systemic accumulation is minimal with topical administration.
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Mometasone furoate is predominantly eliminated via biliary/fecal excretion. After intravenous administration, approximately 74% of the dose is recovered in feces and about 8% in urine. The drug undergoes extensive hepatic metabolism, and metabolites are excreted primarily in bile.
Category C
Category C
Corticosteroid
Corticosteroid, Intranasal